Talphera reports Q2 EPS (10c) vs. (15c) last year

Cash and cash equivalents at June 30, 2025 were $6.8M. “We have enrolled 15 patients in the NEPHRO clinical study and based on the recent accelerated rate of enrollment, we expect to complete the study by the end of the year,” stated Vince Angotti, CEO. “In the last six weeks, we have gained enrollment momentum from the new target profile clinical sites and study protocol changes. New sites have enrolled 90% of patients to date, providing confidence that we are on the right path. To further accelerate the positive enrollment trend, we expect to add six new clinical sites by the end of the third quarter, bringing the total number of sites up to 13, including nine with our target profile. We’re excited about the recent progress of the study, and importantly, the consistent feedback from our sites that they are eager for nafamostat to be available as their preferred alternative to current CRRT anticoagulation products.”